Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

TAVR Versus SAVR in the Era of NSQIP.

Vadlamudi R, Duggan M.

J Cardiothorac Vasc Anesth. 2018 May 26. pii: S1053-0770(18)30370-7. doi: 10.1053/j.jvca.2018.05.037. [Epub ahead of print] No abstract available.

PMID:
30054188
2.

Case Report: Severe Frostbite in Extreme Altitude Climbers-The Kathmandu Iloprost Experience.

Pandey P, Vadlamudi R, Pradhan R, Pandey KR, Kumar A, Hackett P.

Wilderness Environ Med. 2018 Jun 7. pii: S1080-6032(18)30057-7. doi: 10.1016/j.wem.2018.03.003. [Epub ahead of print]

PMID:
29887348
3.

17β-Estradiol Regulates Microglia Activation and Polarization in the Hippocampus Following Global Cerebral Ischemia.

Thakkar R, Wang R, Wang J, Vadlamudi RK, Brann DW.

Oxid Med Cell Longev. 2018 Apr 18;2018:4248526. doi: 10.1155/2018/4248526. eCollection 2018.

4.

Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Liu J, Sareddy GR, Zhou M, Viswanadhapalli S, Li X, Lai Z, Tekmal RR, Brenner A, Vadlamudi RK.

Cancer Res. 2018 Jun 15;78(12):3176-3189. doi: 10.1158/0008-5472.CAN-17-3470. Epub 2018 Apr 16.

PMID:
29661831
5.

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6.

6.

Novel post-transcriptional and post-translational regulation of pro-apoptotic protein BOK and anti-apoptotic protein Mcl-1 determine the fate of breast cancer cells to survive or die.

Onyeagucha B, Subbarayalu P, Abdelfattah N, Rajamanickam S, Timilsina S, Guzman R, Zeballos C, Eedunuri V, Bansal S, Mohammad T, Chen Y, Vadlamudi RK, Rao MK.

Oncotarget. 2017 Sep 12;8(49):85984-85996. doi: 10.18632/oncotarget.20841. eCollection 2017 Oct 17.

7.

Preanesthetic evaluation of the patient with end-stage heart failure.

Sumler M, Vadlamudi R.

Best Pract Res Clin Anaesthesiol. 2017 Jun;31(2):179-188. doi: 10.1016/j.bpa.2017.06.001. Epub 2017 Jun 23. Review.

PMID:
29110791
8.

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK.

Elife. 2017 Aug 8;6. pii: e26857. doi: 10.7554/eLife.26857.

9.

Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.

Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Rao Tekmal R, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR.

Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442.

10.

PELP1: a key mediator of oestrogen signalling and actions in the brain.

Thakkar R, Sareddy GR, Zhang Q, Wang R, Vadlamudi RK, Brann D.

J Neuroendocrinol. 2018 Feb;30(2). doi: 10.1111/jne.12484. Review.

PMID:
28485080
11.

Attitudes and beliefs among high- and low-risk population groups towards β-thalassemia prevention: a cross-sectional descriptive study from India.

Chawla S, Singh RK, Lakkakula BVKS, Vadlamudi RR.

J Community Genet. 2017 Jul;8(3):159-166. doi: 10.1007/s12687-017-0298-4. Epub 2017 Apr 6.

12.

NADPH oxidase in brain injury and neurodegenerative disorders.

Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, Brann DW.

Mol Neurodegener. 2017 Jan 17;12(1):7. doi: 10.1186/s13024-017-0150-7. Review.

13.

HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.

Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK, Manavathi B.

Cell Oncol (Dordr). 2017 Apr;40(2):133-144. doi: 10.1007/s13402-016-0308-2. Epub 2016 Dec 30.

PMID:
28039608
14.

Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.

Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK.

Oncogene. 2017 Apr 27;36(17):2423-2434. doi: 10.1038/onc.2016.395. Epub 2016 Nov 28.

15.

NLRP3 Inflammasome Activation in the Brain after Global Cerebral Ischemia and Regulation by 17β-Estradiol.

Thakkar R, Wang R, Sareddy G, Wang J, Thiruvaiyaru D, Vadlamudi R, Zhang Q, Brann D.

Oxid Med Cell Longev. 2016;2016:8309031. Epub 2016 Oct 23.

16.

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ.

Cancer Res. 2016 Dec 1;76(23):6964-6974. Epub 2016 Sep 26. Erratum in: Cancer Res. 2017 May 15;77(10 ):2770.

17.

Anesthesia and Transesophageal Echocardiography for WATCHMAN Device Implantation.

Mitrev L, Trautman N, Vadlamudi R, Desai N, Sabir SA.

J Cardiothorac Vasc Anesth. 2016 Dec;30(6):1685-1692. doi: 10.1053/j.jvca.2016.06.012. Epub 2016 Jun 8. Review. No abstract available.

PMID:
27595532
18.

Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer.

Yuan B, Cheng L, Gupta K, Chiang HC, Gupta HB, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, Li R.

Oncotarget. 2016 Jul 5;7(27):42585-42597. doi: 10.18632/oncotarget.10018.

19.

Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.

Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2016 Apr 29;6:24185. doi: 10.1038/srep24185.

20.

PELP1: Structure, biological function and clinical significance.

Sareddy GR, Vadlamudi RK.

Gene. 2016 Jul 1;585(1):128-134. doi: 10.1016/j.gene.2016.03.017. Epub 2016 Mar 18. Review.

21.

Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis.

Rajamanickam S, Panneerdoss S, Gorthi A, Timilsina S, Onyeagucha B, Kovalskyy D, Ivanov D, Hanes MA, Vadlamudi RK, Chen Y, Bishop AJ, Arbiser JL, Rao MK.

Clin Cancer Res. 2016 Jul 15;22(14):3524-36. doi: 10.1158/1078-0432.CCR-15-2535. Epub 2016 Feb 29.

22.

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.

Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R, Curiel TJ.

Signal Transduct Target Ther. 2016;1. pii: 16030. doi: 10.1038/sigtrans.2016.30. Epub 2016 Dec 23.

23.

Proline-, glutamic acid-, and leucine-rich protein 1 mediates estrogen rapid signaling and neuroprotection in the brain.

Sareddy GR, Zhang Q, Wang R, Scott E, Zou Y, O'Connor JC, Chen Y, Dong Y, Vadlamudi RK, Brann D.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):E6673-82. doi: 10.1073/pnas.1516729112. Epub 2015 Nov 16.

24.

Cancer therapy using natural ligands that target estrogen receptor beta.

Sareddy GR, Vadlamudi RK.

Chin J Nat Med. 2015 Nov;13(11):801-807. doi: 10.1016/S1875-5364(15)30083-2. Review.

25.

Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.

Dang DN, Raj G, Sarode V, Molberg KH, Vadlamudi RK, Peng Y.

Hum Pathol. 2015 Dec;46(12):1829-35. doi: 10.1016/j.humpath.2015.07.023. Epub 2015 Aug 12.

PMID:
26428280
26.

Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy.

Satsangi A, Roy SS, Satsangi RK, Tolcher AW, Vadlamudi RK, Goins B, Ong JL.

Biomaterials. 2015 Aug;59:88-101. doi: 10.1016/j.biomaterials.2015.03.039. Epub 2015 May 15.

PMID:
25956854
27.

Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.

Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK.

Breast Cancer Res Treat. 2015 Apr;150(3):487-99. doi: 10.1007/s10549-015-3339-x. Epub 2015 Mar 19.

28.

PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Cortez V, Samayoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK.

Cancer Res. 2014 Dec 15;74(24):7395-405. doi: 10.1158/0008-5472.CAN-14-0993. Epub 2014 Nov 6.

29.

Identifying patients most likely to have a common bile duct stone after a positive intraoperative cholangiogram.

Vadlamudi R, Conway J, Mishra G, Baillie J, Gilliam J, Fernandez A, Evans J.

Gastroenterol Hepatol (N Y). 2014 Apr;10(4):240-4.

30.

Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism among Gaddi tribe of Indian state of Himachal Pradesh.

Khan S, Thakur S, Kallur SN, Ghosh PK, Sachdeva MP, Vadlamudi RR.

Ann Hum Biol. 2014 Nov-Dec;41(6):579-81. doi: 10.3109/03014460.2014.920917. Epub 2014 Jun 16.

PMID:
24932671
31.

The social network of PELP1 and its implications in breast and prostate cancers.

Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj GV.

Endocr Relat Cancer. 2014 Aug;21(4):T79-86. doi: 10.1530/ERC-13-0502. Epub 2014 May 23. Review.

32.

Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.

Satsangi A, Roy SS, Satsangi RK, Vadlamudi RK, Ong JL.

Mol Pharm. 2014 Jun 2;11(6):1906-18. doi: 10.1021/mp500128k. Epub 2014 May 21.

PMID:
24847940
33.

Editor's Note.

Vadlamudi RV.

Indian J Pharm Sci. 2014 Jan;76(1):1. No abstract available.

34.

Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.

Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK.

Cell Death Differ. 2014 Sep;21(9):1409-18. doi: 10.1038/cdd.2014.55. Epub 2014 May 2.

35.

Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Gonugunta VK, Sareddy GR, Krishnan SR, Cortez V, Roy SS, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2014 Jun;13(6):1578-88. doi: 10.1158/1535-7163.MCT-13-0877. Epub 2014 Mar 31.

36.

Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.

Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, Brann DW.

Mol Cell Endocrinol. 2014 May 25;389(1-2):84-91. doi: 10.1016/j.mce.2013.12.019. Epub 2014 Feb 6.

37.

Premature menopause and risk of neurological disease: basic mechanisms and clinical implications.

Scott EL, Zhang QG, Vadlamudi RK, Brann DW.

Mol Cell Endocrinol. 2014 May 25;389(1-2):2-6. doi: 10.1016/j.mce.2014.01.013. Epub 2014 Jan 22. Review.

38.

PELP1 oncogenic functions involve alternative splicing via PRMT6.

Mann M, Zou Y, Chen Y, Brann D, Vadlamudi R.

Mol Oncol. 2014 Mar;8(2):389-400. doi: 10.1016/j.molonc.2013.12.012. Epub 2013 Dec 30.

39.

Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, Tekmal RR, Vadlamudi RK.

Oncogene. 2014 Jul 10;33(28):3707-16. doi: 10.1038/onc.2013.332. Epub 2013 Aug 26.

40.

Menarcheal age of type 1 diabetic Bengali Indian females.

Raha O, Sarkar B, Godi S, GhoshRoy A, Pasumarthy V, Chowdhury S; JDRF-India, Vadlamudi RR.

Gynecol Endocrinol. 2013 Nov;29(11):963-6. doi: 10.3109/09513590.2013.819080. Epub 2013 Aug 19.

PMID:
23952104
41.

PELP1 oncogenic functions involve CARM1 regulation.

Mann M, Cortez V, Vadlamudi R.

Carcinogenesis. 2013 Jul;34(7):1468-75. doi: 10.1093/carcin/bgt091. Epub 2013 Mar 13.

42.

Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause.

Zhang QG, Wang RM, Scott E, Han D, Dong Y, Tu JY, Yang F, Reddy Sareddy G, Vadlamudi RK, Brann DW.

Brain. 2013 May;136(Pt 5):1432-45. doi: 10.1093/brain/awt046. Epub 2013 Mar 9.

43.

HLA class II SNP interactions and the association with type 1 diabetes mellitus in Bengali speaking patients of Eastern India.

Raha O, Sarkar B, Lakkakula BV, Pasumarthy V, Godi S, Chowdhury S, Raychaudhuri P, Vadlamudi RR.

J Biomed Sci. 2013 Feb 27;20:12. doi: 10.1186/1423-0127-20-12.

44.

Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization.

Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, Buddavarapu KC, Broaddus R, Hornsby P, Tomlinson G, Dome J, Vadlamudi RK, Pertsemlidis A, Chen Y, Rao MK.

PLoS One. 2012;7(12):e52397. doi: 10.1371/journal.pone.0052397. Epub 2012 Dec 21.

45.

KDM1 is a novel therapeutic target for the treatment of gliomas.

Sareddy GR, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK.

Oncotarget. 2013 Jan;4(1):18-28.

46.

Five friends of methylated chromatin target of protein-arginine-methyltransferase[prmt]-1 (chtop), a complex linking arginine methylation to desumoylation.

Fanis P, Gillemans N, Aghajanirefah A, Pourfarzad F, Demmers J, Esteghamat F, Vadlamudi RK, Grosveld F, Philipsen S, van Dijk TB.

Mol Cell Proteomics. 2012 Nov;11(11):1263-73. doi: 10.1074/mcp.M112.017194. Epub 2012 Aug 7.

47.

Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma.

Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A.

J Cardiothorac Vasc Anesth. 2012 Dec;26(6):1083-93. doi: 10.1053/j.jvca.2012.06.015. Epub 2012 Aug 3. Review. No abstract available.

PMID:
22863406
48.

Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.

Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK.

Breast Cancer Res. 2012 Jul 19;14(4):R108. doi: 10.1186/bcr3229. Erratum in: Breast Cancer Res. 2012;14(6):404.

49.

Therapeutic significance of estrogen receptor β agonists in gliomas.

Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2012 May;11(5):1174-82. doi: 10.1158/1535-7163.MCT-11-0960. Epub 2012 Mar 21.

50.

Emerging significance of estrogen cancer coregulator signaling in breast cancer.

Mann M, Krishnan S, Vadlamudi RK.

Minerva Ginecol. 2012 Feb;64(1):75-88. Review.

PMID:
22334233

Supplemental Content

Loading ...
Support Center